Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Aulenbacher

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Anti-Cancer Drugs|February 1, 1993
A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusionJ A Gietema, H J Guchelaar, E G de Vries, et al.
British Journal of Cancer|February 1, 1993
A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 daysJ A Gietema, E G de Vries, D T Sleijfer, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Anti-Cancer Drugs|February 1, 1993
A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusionJ A Gietema, H J Guchelaar, E G de Vries, et al.
British Journal of Cancer|February 1, 1993
A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 daysJ A Gietema, E G de Vries, D T Sleijfer, et al.
Pageof 2